Clinical trial
Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral…
NCT00330382 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00330382 |
|---|---|
| Title | Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia |
| Official title | Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lip and Oral Cavity Cancer, Oral Leukoplakia, Oropharyngeal Cancer, Tongue Cancer |
| Intervention type | Drug, Other |
| Interventions | Bowman-Birk inhibitor concentrate, placebo, laboratory biomarker analysis |
| Enrollment | 325 |
| Start date | Jan 1, 1999 |
| Primary completion | Jul 1, 2010 |
| Completion | May 1, 2013 |
| First posted | May 26, 2006 |
| Last update posted | Dec 19, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: